News & Comment

Dealmaking is returning to pre-pandemic levels with numerous billion-dollar deals being signed, many focusing on immuno-oncology and inflammation.

CalciMedica, a clinical-stage biopharma company, is developing potentially first-in-class small molecules to combat excessive intracellular calcium levels that drive pathological processes in inflammatory diseases and acute injury, including COVID-19.

As a government funder, the Korea Drug Development Fund (KDDF) invests in promising selected compounds by taking them through assessment and translating them into cutting-edge science for patient benefits and market opportunities.

The city of Phoenix hosts a thriving life-sciences ecosystem that fosters collaboration among industry, education, research and community partners to transform discoveries into health.

Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.

Enterome is using its unique Mimicry approach coupled with the power of partnering to harness the potential of the gut’s natural tolerance pathway to address allergies and autoimmune diseases.

Companies are investing in a range of pioneering strategies in the search for the next therapeutic advances for immuno-inflammatory diseases.

Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.

First Republic Bank’s relationships in the sector help it meet the unique needs of both startups and seasoned life science companies.

Many biotechs completed private financing rounds during Autumn which focused on immunotherapy development and more.

Companies developing microbiome-based therapies have been beset by challenges in the past few years, but hopes remain for some applications and could soon be boosted by the first regulatory approval in the field.

Cell and gene therapy companies continue to attract large deals in 2022, despite the financing landscape looking gloomier than in the previous year.

Solarea Bio is harnessing the diversity of the edible plant microbiota to deliver medical food products that aid the dietary management of inflammatory disorders and support healthy aging.

How a 100-year-old study spawned a novel class of multifunctional neurological treatments.

With Exeliom Biosciences’s drug candidate, EXL01, the long-touted immune-modulation potential of a key gut bacterial species is finally reaching patients in the clinic.

Microbiotica’s platform makes it a leader in precision clinical discovery of novel microbiome-based therapeutics and biomarkers. With the platform validated at scale, and a pipeline of programs, the company is open to collaborations in both therapeutic and biomarker discovery.

Using innovative particle-engineering technology, Alveolus Bio is developing a platform that delivers live biotherapeutic products deep into the lungs for the treatment of chronic and infectious respiratory disease.

Australia’s Microba is leveraging its world-leading microbiome tools and data science for rigorous hypothesis-driven live-biotherapeutics development.

Minaris Regenerative Medicine is developing large-scale 3D cell-production processes and optimizing its culture parameters, as well as enabling in-house batch certification, to enable its partners to realize the huge potential of cell therapies.

Shape Therapeutics is developing next-generation gene-therapy technologies that harness the power of artificial intelligence and RNA editing to repair disease-causing mutations.